(Total Views: 244)
Posted On: 07/29/2022 10:10:15 AM
Post# of 49
$IPA ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2022
https://www.businesswire.com/news/home/202207...-Year-2022
The Company achieved record revenues of $19.4 million, up 8.1% from $17.9 million in fiscal year 2021
The Company achieved record revenues of $5.2 million for the three months ended April 30, 2022, an increase of 7.4% over the same period last year.
The Company achieved an increase in CRO revenue (total revenue minus Talem asset out-licensing revenue) of 15.9% over the same period last year.
VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced financial results for the full fiscal year 2022 ended April 30, 2022.
https://www.businesswire.com/news/home/202207...-Year-2022
The Company achieved record revenues of $19.4 million, up 8.1% from $17.9 million in fiscal year 2021
The Company achieved record revenues of $5.2 million for the three months ended April 30, 2022, an increase of 7.4% over the same period last year.
The Company achieved an increase in CRO revenue (total revenue minus Talem asset out-licensing revenue) of 15.9% over the same period last year.
VICTORIA, British Columbia--(BUSINESS WIRE)--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA), an advanced biotherapeutic research and technology company, today announced financial results for the full fiscal year 2022 ended April 30, 2022.
(0)
(0)
